The Impact of Machine Change Parts in OSD Manufacturing & R&D
The SADE SP 60 Series performs pharmaceutical weight sorting on 100% of tablets and capsules with zero change parts – no chute, bowl, guide, or format kit to swap, clean, or mix up between products.
Regulators treat change parts as product-contact surfaces and contamination vectors, not operational details, and every extra part is another opportunity for residue carryover or a line-clearance failure. Near-universal weight sorting removes that risk at the source, rather than managing it through more procedures.
Regulators Are Explicit: Parts and Shared Equipment Are a Cross-Contamination Hazard
EU/UK/PIC/S frameworks consistently emphasise that shared equipment must manage cross-contamination risk using Quality Risk Management (QRM) – and that includes parts.
Regulatory references
EU GMP Chapter 5 directs QRM to determine the extent of dedication needed, including specific product-contact parts. EU GMP Chapter 3 pushes for design that minimises errors and enables effective cleaning. PIC/S PI 043-1 explicitly lists hazards from movement and mix-up of equipment or parts. ICH Q9(R1) formalises the expectation that manufacturers use risk tools to eliminate failure modes.
Health-based exposure limits
The EMA HBEL guideline frames cross-contamination as a patient risk and provides a scientific basis for threshold levels. PIC/S PI 046-1 transposes HBEL expectations into the PIC/S context for shared facilities.
If a process requires swapping many product-contact parts, it has increased the contamination and mix-up surface area – requiring a heavier control strategy of cleaning validation, verification, training, and deviation exposure. A near-universal sorter changes this equation by removing a significant portion of the hazard.
Inspection Reality: "Change Parts" Are a Repeatable Failure Mode
This isn’t theoretical. Regulators repeatedly cite change parts in inspection findings.
| Source | Finding | ||
|---|---|---|---|
| FDA Form 483, Baxter Pharmaceuticals India (Jan 2023) | Procedures lacked detailed instructions for cleaning change parts of different sizes, shapes, and materials. No cleaning verification. "Cleaned" change parts observed with unknown residues. Line clearance checklists marked parts "not damaged" despite damage being present. | ||
| FDA Warning Letter, Baxter Healthcare Corporation (Jul 2023) | Explicitly calls for an assessment of equipment condition, including change parts, and associated maintenance procedures. |
Change parts fail the same way across all equipment – presses, fillers, packaging lines, and inspection equipment. Product-contact part proliferation consistently expands the failure surface.
The Operational Math: Fewer Parts Means Fewer Failure Opportunities
Risk management principles state that robust control requires reducing the number of steps and interfaces. If a changeover requires n discrete, error-prone actions – swap part A, fit part B, confirm orientation, confirm cleanliness status – and the chance of an error per action is p, then the probability of at least one error is:
1 − (1 − p)n
As n increases, risk rises exponentially.
Systems requiring unique format kits for each tablet or capsule size and type increase n: more part picks from storage, more cleaning and drying steps, more clean/dirty hold management, more inspection points, more documentation and QA release checks, more opportunities for the wrong kit or revision to be used.
A near-universal sorter dramatically reduces n by eliminating the need for dedicated product-contact surfaces. This is especially critical in R&D and CDMO environments, where high-mix, low-volume, frequent changeovers are the norm.
"But Isn't This Just About Speed?" No. It's About GMP Resilience.
While there are efficiency benefits – sometimes significant – the strategic value is resilience: fewer deviations, fewer investigations, fewer unexplained rejects, fewer schedule shocks.
A pharma-sector case study on packaging line changeovers (SMED + lean integration) reported up to 50% reduction in changeover/batch change time and around 25% improvement in OEE (Bevilacqua et al., 2015).
If large parts of the changeover content can be removed – because the equipment doesn’t need dedicated format parts – the starting position is structurally better than training and standard work alone can achieve.
Why This Matters Specifically to Weight Sorting
Weight sorting is often deployed at points where organisations are most sensitive to quality and data decisions: incoming R&D batches and formulation screening, blend/press optimisation and process development, stability studies and investigation samples, batch recovery and salvage decisions, and containment-controlled environments for potent compounds and shared facilities.
In these contexts, the hidden cost of change parts isn’t just the time to swap them – it’s the additional GMP system load a manufacturer must build and maintain around every dedicated format kit.
The Compliance Overhead Created by Format-Part Ecosystems
If a competitor’s sorter requires format kits per product shape or size, the operator inherits a set of standing requirements:
- Unique part identification, status labelling, and revision control.
- Defined cleaning procedures per part type and material.
- Verification of cleaning effectiveness.
- Controlled storage and segregation of clean/dirty parts.
- Line clearance checks, including correct format size verification.
- Investigation readiness when rejects spike post-changeover.
21 CFR § 211.67 reinforces that equipment and utensils must be cleaned and maintained to prevent contamination affecting product quality. A “universal” format capability reduces the number of moving pieces the GMP system must control.
The Strategic Angle: Supporting Modern Manufacturing Strategy
Pharma is trending toward more SKUs and dose strengths, smaller campaigns, faster tech transfer, CDMO models with shared assets, more potent compounds with stricter cross-contamination expectations, and tighter supply continuity expectations.
ICH Q9(R1) pushes the industry to treat quality risk management as part of preventing wider impacts such as supply disruption caused by quality failures. Equipment that needs fewer change parts aligns with that direction: reduce complexity, improve control, shorten release cycles, stay inspection-ready.
A Practical "Numbers" Illustration
Illustrative scenario: a high-mix CDMO sorting 12 products/week. Competitor requires one dedicated kit per format (average 6 parts per kit); each part adds handling steps – retrieve, verify status, fit, clean/store, document. Changeover labour rate: £60/hour.
| Approach | Per changeover | Weekly (12 changeovers) | Labour cost |
|---|---|---|---|
| Competitor (format kits) | 45 min changeover + 20 min checks | 13 hours/week | ≈£780/week (~£40k/year) |
| Near-universal (minimal dedicated parts) | 15 min changeover + 10 min checks | 5 hours/week | ≈£300/week (~£15k/year) |
Format kits also carry deviation exposure – rare but expensive when it occurs.
Indicative Delta:
- ~8 hours/week saved.
- ~£25k/year in direct labour alone, before accounting for scrap/reject swings after changeover, time lost to investigations, extra inventory of spare kits, or cleaning verification effort for multiple part types.
Conclusion: Every eliminated part eliminates a cleaning surface, an ID check, a storage decision, and a potential mix-up.
Conclusion
Format-part complexity is not a minor inconvenience - it's a structural GMP risk.
If an operating model involves frequent changeovers, shared equipment, and high product mix, modern guidance expects risk to be controlled proportionately – and inspection evidence shows change parts are a recurring weak point.
Designing a sorter that needs almost no dedicated change parts is one of the cleanest ways to reduce both contamination/mix-up exposure and the operational burden of controlling them.
CI Precision has manufactured pharmaceutical weighing and inspection equipment for over 50 years, as featured in Manufacturing Chemist.
Ready to Explore High-Throughput Weighing Solutions?
Contact our team to discuss how we can help with your pharmaceutical QC requirements.